Alnylam Rockets to Record High on $1.52B Surge, Claims 38th Spot in Trading Volume

On September 9, 2025, , , ranking 38th in market activity. , reflecting strong investor confidence driven by advancements in RNA interference therapeutics and positive financial performance.

, , and upgraded analyst targets. , . H.C. , . , underscoring KARDIA3 trial outcomes and plans for a cardiovascular outcomes study.

, . The transaction, executed through stock option exercises, is considered routine, . The seller affirmed no undisclosed material adverse information, aligning with standard Rule 10b5-1 compliance.

To run this test rigorously I’ll need a few extra details so I can generate daily trading-day signals correctly and pull the proper data set. 1. Stock universe • Should I use all U.S. common stocks (≈ 4,000–5,000 names) or a smaller universe such as the Russell 3000 or S&P 1500? • Alternatively, if you already have a list of tickers you’d like included, please share it (or a source where I can retrieve it). 2. Trade timing conventions • Entry: Buy at today’s close or tomorrow’s open? • Exit: Sell at tomorrow’s close or tomorrow’s open? (The most common intraday-neutral convention is “buy at today’s close, sell at tomorrow’s close,” but I can follow any rule you prefer). 3. Weighting method • Equal-weight each of the 500 stocks? • Or volume-weighted / dollar-weighted? 4. Transaction costs & slippage • If you’d like to include an estimated round-trip cost (e.g., 10 bps per trade), please specify. Once I have these details I’ll pull the daily volume data, generate the day-by-day “top-500” signal file, and run the back-test from 2022-01-03 (first trading day of 2022) through yesterday’s close.